Effect of Concomitant Medications on Efficacy of Sonidegib 200 Mg Daily in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month Randomized, Double-Blind BOLT Study

Main Article Content

Richard Dummer
Michael Migden
Nicholas Squittieri
Li Liu
Alexander Guminski
John Lear

Keywords

Basal Cell Carcinoma, Sonidegib, concomitant medications, efficacy

Abstract

Abstract not available.

References

1) Xiang F, et al. JAMA Dermatol. 2014; 150:1063–71

2) Asgari MM, et al. JAMA Dermatol. 2015; 151:976–81

3) Amici JM, et al. Eur J Dermatol. 2015; 25:586–94

4) Lear JT, et al. Br J Cancer. 2014; 111:1476–81

5) Cortes JE, et al. Cancer Treat Rev. 2019; 76:41–50

6) Kim JYS, et al. J Am Acad Dermatol. 2018; 78:540–59

7) Odomzo (sonidegib) [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017

8) European Medicines Agency. Summary of Product Characteristics, WC500188762

9) Swissmedic, Authorization Number 65065, 2015

10) Australian Government Department of Health, ARTG 292262

11) Migden MR, et al. Lancet Oncol. 2015; 16:716–28

12) Migden MR, et al. J Clin Oncol. 2018; 36:Suppl abstr 9551

13) Lear JT, et al. J Eur Acad Dermatol Venereol. 2018; 32:372–81

14) Dummer R, et al. J Am Acad Dermatol

Article Sidebar

Poster PDF
Published
Sep 2, 2020
DOI https://doi.org/10.25251/skin.4.supp.68

Article Details

How to Cite
[1]
Dummer, R., Migden, M., Squittieri, N., Liu, L., Guminski, A. and Lear, J. 2020. Effect of Concomitant Medications on Efficacy of Sonidegib 200 Mg Daily in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month Randomized, Double-Blind BOLT Study. SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s69. DOI:https://doi.org/10.25251/skin.4.supp.68.
Issue
Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>